Re-treatment of Paget's Disease
After a single treatment with zoledronic acid injection in Paget's disease an extended remission period is observed. Specific re-treatment data are not available. However, re-treatment with zoledronic acid injection may be considered in patients who have relapsed, based on increases in serum alkaline phosphatase, or in those patients who failed to achieve normalization of their serum alkaline phosphatase, or in those patients with symptoms, as dictated by medical practice.
Prevention of Osteoporosis in Postmenopausal Women
The safety of zoledronic acid injection in postmenopausal women with osteopenia (low bone mass) was assessed in a 2-year randomized, multi-center, double-blind, placebo-controlled study of 581 postmenopausal women aged greater than or equal to 45 years. Patients were randomized to one of three treatment groups: (1) Zoledronic acid injection given at randomization and Month 12 (n=198); (2) Zoledronic acid injection given at randomization and placebo at Month 12 (n=181); and (3) placebo given at randomization and Month 12 (n=202). Zoledronic acid injection was administered as a single 5 mg dose in 100 mL solution infused over at least 15 minutes. All women received 500 to 1200 mg elemental calcium plus 400 to 800 international units vitamin D supplementation per day.
The incidence of serious adverse events was similar for subjects given (1) Zoledronic acid injection at randomization and at Month 12 (10.6%), (2) Zoledronic acid injection at randomization and placebo given at Month 12 (9.4%), and (3) placebo at randomization and at Month 12 (11.4%). The percentages of patients who withdrew from the study due to adverse events were 7.1%, 7.2%, and 3.0% in the two zoledronic acid injection groups and placebo group, respectively. Adverse reactions reported in at least 2% of patients with osteopenia and more frequently in the zoledronic acid injection-treated patients than placebo-treated patients are shown in Table 2.
Table 2. Adverse Reactions Occurring in Greater Than or Equal to 2% of Patients with Osteopenia and More Frequently Than in Placebo-Treated Patients
System Organ Class
| 5 mg IV Zoledronic Acid Injection once per year % (n = 198) | 5 mg IV Zoledronic Acid Injection once % (n = 181) | Placebo once per year % (n = 202) |
Metabolism and Nutrition Disorders | | | |
Anorexia | 2.0 | 0.6 | 0.0 |
Nervous System Disorders | | | |
Headache | 14.6 | 20.4 | 11.4 |
Dizziness | 7.6 | 6.1 | 3.5 |
Hypoesthesia | 5.6 | 2.2 | 2.0 |
Ear and Labyrinth Disorders | | | |
Vertigo | 2.0 | 1.7 | 1.0 |
Vascular Disorders | | | |
Hypertension | 5.1 | 8.3 | 6.9 |
Gastrointestinal Disorders | | | |
Nausea | 17.7 | 11.6 | 7.9 |
Diarrhea | 8.1 | 6.6 | 7.9 |
Vomiting | 7.6 | 5.0 | 4.5 |
Dyspepsia | 7.1 | 6.6 | 5.0 |
Abdominal pain1 | 8.6 | 6.6 | 7.9 |
Constipation | 6.6 | 7.2 | 6.9 |
Abdominal discomfort | 2.0 | 1.1 | 0.5 |
Abdominal distension | 2.0 | 0.6 | 0.0 |
Skin and Subcutaneous Tissue Disorders | | | |
Rash | 3.0 | 2.2 | 2.5 |
Musculoskeletal and Connective Tissue Disorders | | | |
Arthralgia | 27.3 | 18.8 | 19.3 |
Myalgia | 19.2 | 22.7 | 6.9 |
Back pain | 18.2 | 16.6 | 11.9 |
Pain in extremity | 11.1 | 16.0 | 9.9 |
Muscle spasms | 5.6 | 2.8 | 5.0 |
Musculoskeletal pain2 | 8.1 | 7.2 | 7.9 |
Bone pain | 5.1 | 3.3 | 1.0 |
Neck pain | 5.1 | 6.6 | 5.0 |
Arthritis | 4.0 | 2.2 | 1.5 |
Joint stiffness | 3.5 | 1.1 | 2.0 |
Joint swelling | 3.0 | 0.6 | 0.0 |
Flank pain | 2.0 | 0.6 | 0.0 |
Pain in jaw | 2.0 | 3.9 | 2.5 |
General Disorders and Administration-Site Conditions | | | |
Pain | 24.2 | 14.9 | 3.5 |
Pyrexia | 21.7 | 21.0 | 4.5 |
Chills | 18.2 | 18.2 | 3.0 |
Fatigue | 14.6 | 9.9 | 4.0 |
Asthenia | 6.1 | 2.8 | 1.0 |
Peripheral edema | 5.6 | 3.9 | 3.5 |
Non-cardiac chest pain | 3.5 | 7.7 | 3.0 |
Influenza-like illness | 1.5 | 3.3 | 2.0 |
Malaise | 1.0 | 2.2 | 0.5 |
Abbreviation: IV, intravenous or intravenously. 1 Combined abdominal pain, abdominal pain upper, and abdominal pain lower as one Adverse Drug Reaction (ADR). 2 Combined musculoskeletal pain and musculoskeletal chest pain as one ADR. |
Ocular Adverse Events
Cases of iritis/uveitis/episcleritis/conjunctivitis have been reported in patients treated with bisphosphonates, including zoledronic acid. In the osteoporosis prevention trial, 4 (1.1%) patients treated with zoledronic acid injection and 0 (0%) patients treated with placebo developed iritis/uveitis.
Acute Phase Reaction
In patients given zoledronic acid injection at randomization and placebo at Month 12, zoledronic acid injection was associated with signs and symptoms of an acute phase reaction: myalgia (20.4%), fever (19.3%), chills (18.2%), pain (13.8%), headache (13.3%), fatigue (8.3%), arthralgia (6.1%), pain in extremity (3.9%), influenza-like illness (3.3%), and back pain (1.7%), which occurred within the first 3 days following the dose of zoledronic acid injection. The majority of these symptoms were mild to moderate and resolved within 3 days of the event onset but resolution could take up to 7-14 days.
Osteoporosis in Men
The safety of zoledronic acid injection in men with osteoporosis or osteoporosis secondary to hypogonadism was assessed in a two year randomized, multicenter, double-blind, active controlled group study of 302 men aged 25 to 86 years. One hundred fifty three (153) patients were exposed to zoledronic acid injection administered once annually with a 5 mg dose in 100 mL infused over 15 minutes for up to a total of two doses, and 148 patients were exposed to a commercially-available oral weekly bisphosphonate (active control) for up to two years. All participants received 1000 mg of elemental calcium plus 800 to 1000 international units of vitamin D supplementation per day.
The incidence of all-cause mortality (one in each group) and serious adverse events were similar between the zoledronic acid injection and active control treatment groups. The percentage of patients experiencing at least one adverse event was comparable between the zoledronic acid injection and active control groups, with the exception of a higher incidence of post-dose symptoms in the zoledronic acid injection group that occurred within 3 days after infusion. The overall safety and tolerability of zoledronic acid injection was similar to the active control.
Adverse reactions reported in at least 2% of men with osteoporosis and more frequently in the zoledronic acid injection-treated patients than the active control-treated patients and either (1) not reported in the postmenopausal osteoporosis treatment trial or (2) reported more frequently in the trial of osteoporosis in men are presented in Table 3. Therefore, Table 3 should be viewed in conjunction with Table 1.
Table 3: Adverse Reactions Occurring in Greater Than or Equal to 2% of Men with Osteoporosis and More Frequently in the Zoledronic Acid Injection-Treated Patients Than the Active Control-Treated Patients and Either (1) Not Reported in the Postmenopausal Osteoporosis Treatment Trial or (2) Reported More Frequently in This TrialAbbreviation: IV, intravenous or intravenously. 1 Combined abdominal pain, abdominal pain upper, and abdominal pain lower as one Adverse Drug Reaction (ADR). 2 Combined musculoskeletal pain and musculoskeletal chest pain as one ADR. |
System Organ Class
| 5 mg IV Zoledronic Acid Injection once per year % (N = 153) | Active Control once weekly % (N = 148) |
Nervous System Disorders | | |
Headache | 15.0 | 6.1 |
Lethargy | 3.3 | 1.4 |
Eye Disorders | | |
Eye pain | 2.0 | 0.0 |
Cardiac Disorders | | |
Atrial fibrillation | 3.3 | 2.0 |
Palpitations | 2.6 | 0.0 |
Respiratory, Thoracic and Mediastinal Disorders | | |
Dyspnea | 6.5 | 4.7 |
Abdominal pain1 | 7.9 | 4.1 |
Skin and Subcutaneous Tissue Disorders | | |
Hyperhidrosis | 2.6 | 2.0 |
Musculoskeletal, Connective Tissue and Bone Disorders | | |
Myalgia | 19.6 | 6.8 |
Musculoskeletal pain2 | 12.4 | 10.8 |
Musculoskeletal stiffness | 4.6 | 0.0 |
Renal and Urinary Disorders | | |
Blood creatinine increased | 2.0 | 0.7 |
General Disorders and Administrative-Site Conditions | | |
Fatigue | 17.6 | 6.1 |
Pain | 11.8 | 4.1 |
Chills | 9.8 | 2.7 |
Influenza-like illness | 9.2 | 2.0 |
Malaise | 7.2 | 0.7 |
Acute phase reaction | 3.9 | 0.0 |
Investigations | | |
C-reactive protein increased | 4.6 | 1.4 |
Renal Impairment
Creatinine clearance was measured annually prior to dosing and changes in long-term renal function over 24 months were comparable in the zoledronic acid injection and active control groups [see Warnings and Precautions (5.3)].
Acute Phase Reaction
Zoledronic acid injection was associated with signs and symptoms of an acute phase reaction: myalgia (17.1%), fever (15.7%), fatigue (12.4%), arthralgia (11.1%), pain (10.5%), chills (9.8%), headache (9.8%), influenza-like illness (8.5%), malaise (5.2%), and back pain (3.3%), which occurred within the first 3 days following the dose of zoledronic acid injection. The majority of these symptoms were mild to moderate and resolved within 3 days of the event onset but resolution could take up to 7 to 14 days. The incidence of these symptoms decreased with subsequent doses of zoledronic acid injection.
Atrial Fibrillation
The incidence of all atrial fibrillation adverse events in the zoledronic acid injection treatment group was 3.3% (5 out of 153) compared to 2.0% (3 out of 148) in the active control group. However, there were no patients with adjudicated serious adverse events of atrial fibrillation in the zoledronic acid injection treatment group.
Laboratory Findings
There were no patients who had treatment emergent serum calcium levels below 7.5 mg/dL.
Injection-Site Reactions
There were 4 patients (2.6%) on zoledronic acid injection vs. 2 patients (1.4%) on active control with local-site reactions.
Osteonecrosis of the Jaw
In this trial, there were no cases of ONJ [see Warnings and Precautions (5.4)].
Glucocorticoid-Induced Osteoporosis
The safety of zoledronic acid injection in men and women in the treatment and prevention of glucocorticoid-induced osteoporosis was assessed in a randomized, multicenter, double-blind, active controlled, stratified study of 833 men, and women aged 18 to 85 years treated with greater than or equal to 7.5 mg/day oral prednisone (or equivalent). Patients were stratified according to the duration of their pre-study corticosteroid therapy: less than or equal to 3 months prior to randomization (prevention subpopulation), and greater than 3 months prior to randomization (treatment subpopulation).
The duration of the trial was one year with 416 patients exposed to zoledronic acid injection administered once as a single 5 mg dose in 100 mL infused over 15 minutes, and 417 patients exposed to a commercially-available oral daily bisphosphonate (active control) for one year. All participants received 1000 mg of elemental calcium plus 400 to 1000 international units of vitamin D supplementation per day.
The incidence of all-cause mortality was similar between treatment groups: 0.9% in the zoledronic acid injection group and 0.7% in the active control group. The incidence of serious adverse events was similar between the zoledronic acid injection treatment and prevention groups, 18.4% and 18.1%, respectively, and the active control treatment and prevention groups, 19.8% and 16.0%, respectively. The percentage of subjects who withdrew from the study due to adverse events was 2.2% in the zoledronic acid injection group vs. 1.4% in the active control group. The overall safety and tolerability were similar between zoledronic acid injection and active control groups with the exception of a higher incidence of post-dose symptoms in the zoledronic acid injection group that occurred within 3 days after infusion. The overall safety and tolerability profile of zoledronic acid injection in glucocorticoid-induced osteoporosis was similar to the adverse events reported in the zoledronic acid injection postmenopausal osteoporosis clinical trial.
Adverse reactions reported in at least 2% of patients that were either not reported in the postmenopausal osteoporosis treatment trial or reported more frequently in the treatment and prevention of glucocorticoid-induced osteoporosis trial included the following: abdominal pain (zoledronic acid injection 7.5%; active control 5.0%), and musculoskeletal pain (zoledronic acid injection 3.1%; active control 1.7%). Other musculoskeletal events included back pain (zoledronic acid injection 4.3%, active control 6.2%), bone pain (zoledronic acid injection 3.1%, active control 2.2%), and pain in the extremity (zoledronic acid injection 3.1%, active control 1.2%). In addition, the following adverse events occurred more frequently than in the postmenopausal osteoporosis trial: nausea (zoledronic acid injection 9.6%; active control 8.4%), and dyspepsia (zoledronic acid injection 5.5%; active control 4.3%).
Renal Impairment
Renal function measured prior to dosing and at the end of the 12-month study was comparable in the zoledronic acid injection and active control groups [see Warnings and Precautions (5.3)].
Acute Phase Reaction
Zoledronic acid injection was associated with signs and symptoms of a transient acute phase reaction that was similar to that seen in the zoledronic acid injection postmenopausal osteoporosis clinical trial.
Atrial Fibrillation
The incidence of atrial fibrillation adverse events was 0.7% (3 of 416) in the zoledronic acid injection group compared to no adverse events in the active control group. All subjects had a prior history of atrial fibrillation and no cases were adjudicated as serious adverse events. One patient had atrial flutter in the active control group.
Laboratory Findings
There were no patients who had treatment emergent serum calcium levels below 7.5 mg/dL.
Injection-Site Reactions
There were no local reactions at the infusion site.
Osteonecrosis of the Jaw
In this trial there were no cases of ONJ [see Warnings and Precautions (5.4)].
Paget's Disease of Bone
In the Paget's disease trials, two 6-month, double-blind, comparative, multinational studies of 349 men, and women aged greater than 30 years with moderate to severe disease and with confirmed Paget's disease of bone, 177 patients were exposed to zoledronic acid injection and 172 patients exposed to risedronate. Zoledronic acid injection was administered once as a single 5 mg dose in 100 mL solution infused over at least 15 minutes. Risedronate was given as an oral daily dose of 30 mg for 2 months.
The incidence of serious adverse events was 5.1% in the zoledronic acid injection group and 6.4% in the risedronate group. The percentage of patients who withdrew from the study due to adverse events was 1.7% and 1.2% for the zoledronic acid injection and risedronate groups, respectively.
Adverse reactions occurring in at least 2% of the Paget's patients receiving zoledronic acid injection (single 5 mg intravenous infusion) or risedronate (30 mg oral daily dose for 2 months) over a 6-month study period are listed by system organ class in Table 4.
Table 4. Adverse Reactions Reported in at Least 2% of Paget's Patients Receiving Zoledronic Acid Injection (Single 5 mg Intravenous Infusion) or Risedronate (Oral 30 mg Daily for 2 Months) Over a 6-Month Follow-up Period | System Organ Class | 5 mg IV Zoledronic Acid Injection % (N = 177) | 30 mg/day x 2 Months risedronate % (N = 172) |
| Infections and Infestations | | |
| Influenza | 7 | 5 |
| Metabolism and Nutrition Disorders | | |
| Hypocalcemia | 3 | 1 |
| Anorexia | 2 | 2 |
| Nervous System Disorders | | |
| Headache | 11 | 10 |
| Dizziness | 9 | 4 |
| Lethargy | 5 | 1 |
| Paresthesia | 2 | 0 |
| Respiratory, Thoracic and Mediastinal Disorders | | |
| Dyspnea | 5 | 1 |
| Gastrointestinal Disorders | | |
| Nausea | 9 | 6 |
| Diarrhea | 6 | 6 |
| Constipation | 6 | 5 |
| Dyspepsia | 5 | 4 |
| Abdominal distension | 2 | 1 |
| Abdominal pain | 2 | 2 |
| Vomiting | 2 | 2 |
| Abdominal pain upper | 1 | 2 |
| Skin and Subcutaneous Tissue Disorders | | |
| Rash | 3 | 2 |
| Musculoskeletal, Connective Tissue and Bone Disorders |
| Arthralgia | 9 | 11 |
| Bone pain | 9 | 5 |
| Myalgia | 7 | 4 |
| Back pain | 4 | 7 |
| Musculoskeletal stiffness | 2 | 1 |
| General Disorders and Administrative-Site Conditions |
| Influenza-like illness | 11 | 6 |
| Pyrexia | 9 | 2 |
| Fatigue | 8 | 4 |
| Rigors | 8 | 1 |
| Pain | 5 | 4 |
| Peripheral edema | 3 | 1 |
| Asthenia | 2 | 1 |
| Abbreviation: IV, intravenous or intravenously. |
Laboratory Findings
In the Paget's disease trials, early, transient decreases in serum calcium and phosphate levels were observed. Approximately 21% of patients had serum calcium levels less than 8.4 mg/dL 9 to 11 days following zoledronic acid injection administration.
Renal Impairment
In clinical trials in Paget's disease, there were no cases of renal deterioration following a single 5 mg 15-minute infusion [see Warnings and Precautions (5.3)].
Acute Phase Reaction
The signs and symptoms of acute phase reaction (influenza-like illness, pyrexia, myalgia, arthralgia, and bone pain) were reported in 25% of patients in the zoledronic acid injection-treated group compared to 8% in the risedronate-treated group. Symptoms usually occur within the first 3 days following zoledronic acid injection administration. The majority of these symptoms resolved within 4 days of onset.
Osteonecrosis of the Jaw
Osteonecrosis of the jaw has been reported with zoledronic acid [see Warnings and Precautions (5.4)].
Risk Summary
Available data on the use of zoledronic acid injection in pregnant women are insufficient to inform a drug-associated risk of adverse maternal or fetal outcomes. Discontinue zoledronic acid injection when pregnancy is recognized.
In animal reproduction studies, daily subcutaneous administration of zoledronic acid to pregnant rats during organogenesis resulted in increases in fetal skeletal, visceral, and external malformations, decreases in postimplantation survival, and decreases in viable fetuses and fetal weight starting at doses equivalent to 2 times the recommended human 5 mg intravenous dose (based on AUC). Subcutaneous administration of zoledronic acid to rabbits during organogenesis did not cause adverse fetal effects at up to 0.4 times the human 5 mg intravenous dose (based on body surface area, mg/m2), but resulted in maternal mortality and abortion associated with hypocalcemia starting at doses equivalent to 0.04 times the human 5 mg intravenous dose. Subcutaneous dosing of female rats from before mating through gestation and lactation and allowed to deliver caused maternal dystocia and periparturient mortality, increases in stillbirths and neonatal deaths, and reduced pup body weight starting at doses equivalent to 0.1 times the human 5 mg intravenous dose (based on AUC) (see Data).
Bisphosphonates are incorporated into the bone matrix, from which they are gradually released over a period of years. The amount of bisphosphonate incorporated into adult bone, and available for release into the systemic circulation is directly related to the dose and duration of bisphosphonate use. Consequently, based on the mechanism of action of bisphosphonates, there is a potential risk of fetal harm, predominantly skeletal, if a woman becomes pregnant after completing a course of bisphosphonate therapy. The impact of variables, such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration (intravenous versus oral) on the risk has not been studied.
The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data
Animal Data
In pregnant rats given daily subcutaneous doses of zoledronic acid of 0.1, 0.2, or 0.4 mg/kg during organogenesis, fetal skeletal, visceral, and external malformations, increases in pre- and post-implantation loss, and decreases in viable fetuses and fetal weight were observed at 0.2 and 0.4 mg/kg/day (equivalent to 2 and 4 times the human 5 mg intravenous dose, based on AUC). Adverse fetal skeletal effects at 0.4 mg/kg/day (4 times the human 5 mg dose) included unossified or incompletely ossified bones, thickened, curved or shortened bones, wavy ribs, and shortened jaw. Other adverse fetal effects at this dose included reduced lens, rudimentary cerebellum, reduction or absence of liver lobes, reduction of lung lobes, vessel dilation, cleft palate, and edema. Skeletal variations were observed in all groups starting at 0.1 mg/kg/day (1.2 times the human 5 mg dose). Signs of maternal toxicity, including reduced body weight and food consumption were observed at 0.4 mg/kg/day (4 times the human 5 mg dose).
In pregnant rabbits given daily subcutaneous doses of zoledronic acid of 0.01, 0.03, or 0.1 mg/kg during gestation, no adverse fetal effects were observed up to 0.1 mg/kg/day (0.4 times the human 5 mg intravenous dose, based on body surface area, mg/m2). Maternal mortality and abortion were observed in all dose groups (starting at 0.04 times the human 5 mg dose). Adverse maternal effects were associated with drug-induced hypocalcemia.
In female rats given daily subcutaneous doses of 0.01, 0.03, or 0.1 mg/kg, beginning 15 days before mating and continuing through gestation, parturition and lactation, dystocia and periparturient mortality were observed in pregnant rats allowed to deliver starting at 0.01 mg/kg/day (0.1 times the human 5 mg intravenous dose, based on AUC). Also, there was an increase in stillbirths and a decrease in neonate survival starting at 0.03 mg/kg/day (0.3 times the human 5 mg dose), while the number of viable newborns and pup body weight on postnatal Day 7 were decreased at 0.1 mg/kg/day (equivalent to the human 5 mg dose). Maternal and neonatal deaths were considered related to drug-induced periparturient hypocalcemia.
Risk Summary
There are no data on the presence of zoledronic acid in human milk, the effects on the breast-fed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for zoledronic acid injection and any potential adverse effects on the breast-fed child from zoledronic acid injection or from the underlying maternal condition.
Infertility
There are no data available in humans. Female fertility may be impaired based on animal studies demonstrating adverse effects of zoledronic acid injection on fertility parameters [see Nonclinical Toxicology (13.1)].
Distribution
Single or multiple (every 28 days) 5-minute or 15-minute infusions of 2, 4, 8, or 16 mg zoledronic acid were given to 64 patients with cancer and bone metastases. The post-infusion decline of zoledronic acid concentrations in plasma was consistent with a triphasic process showing a rapid decrease from peak concentrations at end-of-infusion to less than 1% of Cmax 24 hours post infusion with population half-lives of t1/2α 0.24 hour and t1/2β 1.87 hours for the early disposition phases of the drug. The terminal elimination phase of zoledronic acid was prolonged, with very low concentrations in plasma between Days 2 and 28 post infusion, and a terminal elimination half-life t1/2γ of 146 hours. The area under the plasma concentration versus time curve (AUC0-24h) of zoledronic acid was dose proportional from 2 to 16 mg. The accumulation of zoledronic acid measured over three cycles was low, with mean AUC0-24h ratios for cycles 2 and 3 versus 1 of 1.13 ± 0.30 and 1.16 ± 0.36, respectively.
In vitro and ex vivo studies showed low affinity of zoledronic acid for the cellular components of human blood. In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL.
Metabolism
Zoledronic acid does not inhibit human P450 enzymes in vitro. Zoledronic acid does not undergo biotransformation in vivo. In animal studies, less than 3% of the administered intravenous dose was found in the feces, with the balance either recovered in the urine or taken up by bone, indicating that the drug is eliminated intact via the kidney. Following an intravenous dose of 20 nCi 14C-zoledronic acid in a patient with cancer and bone metastases, only a single radioactive species with chromatographic properties identical to those of parent drug was recovered in urine, which suggests that zoledronic acid is not metabolized.
Excretion
In 64 patients with cancer and bone metastases on average (± SD) 39 ± 16% of the administered zoledronic acid dose was recovered in the urine within 24 hours, with only trace amounts of drug found in urine post Day 2. The cumulative percent of drug excreted in the urine over 0 to 24 hours was independent of dose. The balance of drug not recovered in urine over 0 to 24 hours, representing drug presumably bound to bone, is slowly released back into the systemic circulation, giving rise to the observed prolonged low plasma concentrations. The 0 to 24 hour renal clearance of zoledronic acid was 3.7 ± 2.0 L/h.
Zoledronic acid clearance was independent of dose but dependent upon the patient's creatinine clearance. In a study in patients with cancer and bone metastases, increasing the infusion time of a 4 mg dose of zoledronic acid from 5 minutes (n = 5) to 15 minutes (n = 7) resulted in a 34% decrease in the zoledronic acid concentration at the end of the infusion ([mean ± SD] 403 ± 118 ng/mL vs. 264 ± 86 ng/mL) and a 10% increase in the total AUC (378 ± 116 ng x h/mL vs. 420 ± 218 ng x h/mL). The difference between the AUC means was not statistically significant.
Specific Populations
Pediatrics
Zoledronic acid injection is not indicated for use in children [see Pediatric Use (8.4)].
Geriatrics
The pharmacokinetics of zoledronic acid was not affected by age in patients with cancer and bone metastases whose age ranged from 38 years to 84 years.
Race
The pharmacokinetics of zoledronic acid was not affected by race in patients with cancer and bone metastases.
Hepatic Impairment
No clinical studies were conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of zoledronic acid.
Renal Impairment
The pharmacokinetic studies conducted in 64 cancer patients represented typical clinical populations with normal to moderately-impaired renal function. Compared to patients with creatinine clearance greater than 80 mL/min (N = 37), patients with creatinine clearance = 50 to 80 mL/min (N = 15) showed an average increase in plasma AUC of 15%, whereas patients with creatinine clearance = 30 to 50 mL/min (N = 11) showed an average increase in plasma AUC of 43%. No dosage adjustment is required in patients with a creatinine clearance of greater than or equal to 35 mL/min. Zoledronic acid injection is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see Contraindications (4), Warnings and Precautions (5.3), Use in Specific Populations (8.6)].
Carcinogenesis
Lifetime carcinogenicity bioassays were conducted in mice and rats. Mice were given daily oral doses of zoledronic acid of 0.1, 0.5, or 2 mg/kg/day for 2 years. There was an increased incidence of Harderian gland adenomas in males and females in all treatment groups (starting at doses equivalent to 0.002 times the human 5 mg intravenous dose, based on body surface area, mg/m2). Rats were given daily oral doses of zoledronic acid of 0.1, 0.5, or 2 mg/kg/day for 2 years. No increased incidence of tumors was observed at any dose (up to 0.1 times the human intravenous dose of 5 mg, based on body surface area, mg/m2).
Mutagenesis
Zoledronic acid was not genotoxic in the Ames bacterial mutagenicity assay, in the Chinese hamster ovary cell assay, or in the Chinese hamster gene mutation assay, with or without metabolic activation. Zoledronic acid was not genotoxic in the in vivo rat micronucleus assay.
Impairment of Fertility
Female rats were given daily subcutaneous doses of zoledronic acid of 0.01, 0.03, or 0.1 mg/kg beginning 15 days before mating and continuing through gestation. Inhibition of ovulation and a decrease in the number of pregnant rats were observed at 0.1 mg/kg/day (equivalent to the human 5 mg intravenous dose, based on AUC). An increase in preimplantation loss and a decrease in the number of implantations and live fetuses were observed at 0.03 and 1 mg/kg/day (0.3 to 1 times the human 5 mg human intravenous dose).
Bone Safety Studies
Zoledronic acid is a potent inhibitor of osteoclastic bone resorption. In the ovariectomized rat, single IV doses of zoledronic acid of 4 to 500 mcg/kg (0.1 to 3.5 times the human 5 mg intravenous dose, based on body surface area, mg/m2) suppressed bone turnover and protected against trabecular bone loss, cortical thinning and the reduction in vertebral and femoral bone strength in a dose-dependent manner. At a dose equivalent to human exposure at the 5 mg intravenous dose, the effect persisted for 8 months, which corresponds to approximately 8 remodeling cycles or 3 years in humans.
In ovariectomized rats and monkeys, weekly treatment with zoledronic acid dose-dependently suppressed bone turnover and prevented the decrease in cancellous and cortical BMD and bone strength, at yearly cumulative doses up to 3.5 times the human 5 mg intravenous dose, based on body surface area, mg/m2. Bone tissue was normal and there was no evidence of a mineralization defect, no accumulation of osteoid, and no woven bone.
The reductions in hip fractures over three years were greater for zoledronic acid injection than placebo regardless of femoral neck BMD T-score.
Effect on All Clinical Fractures
Zoledronic acid injection demonstrated superiority to placebo in reducing the incidence of all clinical fractures, clinical (symptomatic) vertebral and non-vertebral fractures (excluding finger, toe, facial, and clinical thoracic and lumbar vertebral fractures). All clinical fractures were verified based on the radiographic and/or clinical evidence. A summary of results is presented in Table 6.
Table 6. Between-Treatment Comparisons of the Incidence of Clinical Fracture Variables Over 3 YearsOutcome | Zoledronic Acid Injection (N = 3875) Event Rate n (%)2 | Placebo (N = 3861) Event Rate n (%)2 | Absolute Reduction in Fracture Incidence % (95% CI)2 | Relative Risk Reduction in Fracture Incidence % (95% CI) |
Any clinical fracture3 | 308 (8.4) | 456 (12.8) | 4.4 (3.0, 5.8) | 33 (23, 42)** |
Clinical vertebral fracture4 | 19 (0.5) | 84 (2.6) | 2.1 (1.5, 2.7) | 77 (63, 86)** |
Non-vertebral fracture5 | 292 (8.0) | 388 (10.7) | 2.7 (1.4, 4.0) | 25 (13, 36)1 |
1 p-value < 0.001, **p-value < 0.0001. 2 Event rates based on Kaplan-Meier estimates at 36 months 3 Excluding finger, toe, and facial fractures. 4 Includes clinical thoracic and clinical lumbar vertebral fractures. 5 Excluding finger, toe, facial, and clinical thoracic and lumbar vertebral fractures. |
Effect on Bone Mineral Density
Zoledronic acid injection significantly increased BMD at the lumbar spine, total hip and femoral neck, relative to treatment with placebo at time points 12, 24, and 36 months. Treatment with zoledronic acid injection resulted in a 6.7% increase in BMD at the lumbar spine, 6.0% at the total hip, and 5.1% at the femoral neck, over 3 years as compared to placebo.
Bone Histology
Bone biopsy specimens were obtained between Months 33 and 36 from 82 postmenopausal patients with osteoporosis treated with 3 annual doses of zoledronic acid injection. Of the biopsies obtained, 81 were adequate for qualitative histomorphometry assessment, 59 were adequate for partial quantitative histomorphometry assessment, and 38 were adequate for full quantitative histomorphometry assessment. Micro CT analysis was performed on 76 specimens. Qualitative, quantitative and micro CT assessments showed bone of normal architecture and quality without mineralization defects.
Effect on Height
In the 3-year osteoporosis study, standing height was measured annually using a stadiometer. The zoledronic acid injection group revealed less height loss compared to placebo (4.2 mm vs. 7.0 mm, respectively [p < 0.001]).
Study 2: The efficacy and safety of zoledronic acid injection in the treatment of patients with osteoporosis who suffered a recent low-trauma hip fracture was demonstrated in Study 2, a randomized, double-blind, placebo controlled, multinational endpoint study of 2127 men and women aged 50 to 95 years (mean age of 74.5). Concomitant osteoporosis therapies excluding other bisphosphonates and parathyroid hormone were allowed. Zoledronic acid injection was administered once a year as a single 5 mg dose in 100 mL solution, infused over at least 15 minutes. The study continued until at least 211 patients had confirmed clinical fractures in the study population. Vitamin D levels were not routinely measured but a loading dose of vitamin D (50,000 to 125,000 international units orally or IM) was given to patients and they were started on 1000 to 1500 mg of elemental calcium plus 800 to 1200 international units of vitamin D supplementation per day for at least 14 days prior to the study drug infusions. The primary efficacy variable was the incidence of clinical fractures over the duration of the study.
Zoledronic acid injection significantly reduced the incidence of any clinical fracture by 35%. There was also a 46% reduction in the risk of a clinical vertebral fracture (Table 7).
Table 7. Between-Treatment Comparisons of the Incidence of Key Clinical Fracture VariablesOutcome | Zoledronic Acid Injection (N = 1065) Event Rate n (%)2 | Placebo (N = 1062) Event Rate n (%)2 | Absolute Reduction in Fracture Incidence % (95% CI)2 | Relative Risk Reduction in Fracture Incidence % (95% CI) |
Any clinical fracture3 | 92 (8.6) | 139 (13.9) | 5.3 (2.3, 8.3) | 35 (16, 50)** |
Clinical vertebral fracture4 | 21 (1.7) | 39 (3.8) | 2.1 (0.5, 3.7) | 46 (8, 68)1 |
1 p-value < 0.05, **p-value < 0.005. 2 Event rates based on Kaplan-Meier estimates at 24 months. 3 Excluding finger, toe and facial fractures. 4 Including clinical thoracic and clinical lumbar vertebral fractures. |
Effect on Bone Mineral Density
Zoledronic acid injection significantly increased BMD relative to placebo at the hip and femoral neck at all timepoints (12, 24, and 36 months). Treatment with zoledronic acid injection resulted in a 6.4% increase in BMD at the total hip and a 4.3% increase at the femoral neck over 36 months as compared to placebo.
Handling
After opening the solution, it is stable for 24 hours at 2° to 8°C (36° to 46°F).
If refrigerated, allow the refrigerated solution to reach room temperature before administration.
Information for Patients
Patients should be made aware that zoledronic acid injection contains the same active ingredient (zoledronic acid) found in Zometa®, and that patients being treated with Zometa® should not be treated with zoledronic acid injection.
Zoledronic acid injection is contraindicated in patients with creatinine clearance less than 35 mL/min [see Contraindications (4)].
Before being given zoledronic acid injection, patients should tell their doctor if they have kidney problems and what medications they are taking [see Warnings and Precautions (5.3)].
Zoledronic acid injection should not be given if the patient is pregnant or plans to become pregnant, or if she is breastfeeding [see Use in Specific Populations (8.1, 8.2, 8.3)].
There have been reports of bronchoconstriction in aspirin-sensitive patients receiving bisphosphonates, including zoledronic acid injection. Before being given zoledronic acid injection, patients should tell their doctor if they are aspirin-sensitive.
If the patient had surgery to remove some or all of the parathyroid glands in their neck, or had sections of their intestine removed, or are unable to take calcium supplements they should tell their doctor.
Zoledronic acid injection is given as an infusion into a vein by a nurse or a doctor, and the infusion time must not be less than 15 minutes.
On the day of treatment the patient should eat and drink normally, which includes drinking at least 2 glasses of fluid, such as water within a few hours prior to the infusion, as directed by their doctor, before receiving zoledronic acid injection.
After getting zoledronic acid injection it is strongly recommended patients with Paget's disease take calcium in divided doses (for example, 2 to 4 times a day) for a total of 1500 mg calcium a day to prevent low blood calcium levels. This is especially important for the two weeks after getting zoledronic acid injection [see Warnings and Precautions (5.2)].
Adequate calcium and vitamin D intake is important in patients with osteoporosis and the current recommended daily intake of calcium is 1200 mg and vitamin D is 800 international units to 1000 international units daily. All patients should be instructed on the importance of calcium and vitamin D supplementation in maintaining serum calcium levels.
Patients should be aware of the most commonly associated side effects of therapy. Patients may experience one or more side effects that could include: fever, flu-like symptoms, myalgia, arthralgia, and headache. Most of these side effects occur within the first 3 days following the dose of zoledronic acid injection. They usually resolve within 3 days of onset but may last for up to 7 to 14 days. Patients should consult their physician if they have questions or if these symptoms persist. The incidence of these symptoms decreased markedly with subsequent doses of zoledronic acid injection.
Administration of acetaminophen following zoledronic acid injection administration may reduce the incidence of these symptoms.
Physicians should inform their patients that there have been reports of persistent pain and/or a non-healing sore of the mouth or jaw, primarily in patients treated with bisphosphonates for other illnesses. During treatment with zoledronic acid, patients should be instructed to maintain good oral hygiene and undergo routine dental check-ups. If they experience any oral symptoms, they should immediately report them to their physician or dentist.
Severe and occasionally incapacitating bone, joint, and/or muscle pain have been infrequently reported in patients taking bisphosphonates, including zoledronic acid injection. Consider withholding future zoledronic acid injection treatment if severe symptoms develop.
Atypical femur fractures in patients on bisphosphonate therapy have been reported; patients with thigh or groin pain should be evaluated to rule out a femoral fracture.
Brands listed are the trademarks of their respective owners.
meitheal®
Mfd. for Meitheal Pharmaceuticals
Chicago, IL 60631 (USA)
©2026 Meitheal Pharmaceuticals Inc.
Mfd. by Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Nanjing, China 210061
Product of Argentina
Revised: June 2026
8C9AAM9-01